Special issue of Evidence-Based Oncology focuses on benefits and challenges of APMs in cancer care

The revolution in how physicians will be paid brings unique challenges to cancer care, where individual patient needs may make costs hard to predict. As oncologists and payers adapt to this new environment, Evidence-Based Oncology, a publication of The American Journal of Managed Care, has published a special issue on the benefits and challenges of alternate payment models (APMs), which are encouraged under the Medicare Access and CHIP Reauthorization Act (MACRA).

The traditional definition of value—costs over outcomes—cannot always incorporate the clinical and diagnostic risks that oncologists take in deciding how to proceed, writes Joseph Alvarnas, MD, director of Value-Based Analytics at City of Hope and editor-in-chief of EBO.

"Value has become a catchword in healthcare," Alvarnas writes. "This has been true for a while already within the domain of cancer care, where the extraordinary complexity and intensity of effective care, coupled with the astronomical prices of new anticancer agents, have led many to question the economic sustainability of delivering effective and innovative care to this population of patients."

In this special issue:

  • Authors from Deloitte say financial incentives cannot be the only factor driving adoption of APMs. They compare the benefits of new approaches, including CMS' Oncology Care Model.
  • Authors from the American Society of Clinical Oncology (ASCO) and practicing oncologists discuss ASCO's Patient-Centered Oncology Payment model, which they say addresses both the Triple Aim—increased patient satisfaction, improved outcomes, and lower costs—and a fourth element: improving life for providers.
  • Jeffrey W. Chell, CEO of the National Marrow Donor Program, writes that Medicare must standardize reimbursement policies so that providers do not lose money for transplants to treat blood disorders.
  • Authors from Flatiron Health discuss the day-to-day problems of making APMs work, and how technology is essential to overcome them.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Groundbreaking technology converts cancer cells into normal cells